Genmab has appointed Margarida Duarte as general manager, Europe and emerging markets, as the company strengthens its commercial operations ahead of future product launches.

The role will see Duarte oversee Genmab’s business across European and emerging markets, with responsibility for commercial execution, organisational alignment and launch readiness. The move comes as the company continues to expand its presence beyond research into full-scale commercialisation of antibody-based medicines.

Genmab chief commercial officer Brad Bailey said: “Margarida’s proven ability to build and scale high-performing organizations, deliver successful oncology launches across complex markets, and lead through transformation make her exceptionally well suited to accelerate our momentum in Europe and expand our impact for patients.”

Duarte brings more than 20 years of biotech leadership experience spanning oncology, haematology and rare diseases. Most recently, she served as executive vice president and chief commercial officer at Deciphera Pharmaceuticals, where she led global commercial operations and supported the company’s transition into a multi-product organisation.

Earlier in her career, she held senior roles at Alnylam Pharmaceuticals, Exelixis, Onyx Pharmaceuticals and Amgen, where she led European commercial strategy and supported multiple oncology product launches across complex healthcare systems.

Duarte said: “I am proud to join Genmab, a company recognised for its pioneering antibody science and strong commitment to patients. I look forward to partnering with colleagues across our markets and engaging with external stakeholders to help broaden the impact of our innovative antibody-based medicines for patients.”

Genmab, founded in 1999 and headquartered in Copenhagen, is focused on the development of antibody-based therapies for cancer and other serious diseases. The company said the appointment supports its broader strategy to scale commercial capabilities in Europe and prepare for upcoming product launches.

Duarte will be based at Genmab’s European commercial headquarters in Zug, Switzerland, and will report to Brad Bailey, executive vice president and chief commercial officer.

The appointment reflects ongoing investment by biotech companies in experienced commercial leadership as pipelines mature and organisations shift from research-focused models to global product deployment.